Abstract
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder characterized clinically by various combinations of parkinsonian, autonomic, cerebellar, or pyramidal symptoms and signs and pathologically by cell loss, gliosis, and glial cytoplasmic inclusions in several brain and spinal cord structures. The term MSA was introduced in 1969, however cases of MSA were previously reported under the rubrics of striatonigral degeneration, olivopontocerebellar atrophy, Shy-Drager syndrome and idiopathic orthostatic hypotension. In the late 1990s, α-synuclein immunostaining was recognized as most sensitive marker of inclusion pathology in MSA: because of these advances in molecular pathogenesis, MSA has been firmly established as α-synucleinopathy along with Parkinson’s disease (PD) and dementia with Lewy bodies. Recent epidemiological surveys have shown that MSA is not a rare disorder (∼5 cases per 100,000 population), and that misdiagnosis, especially with PD, is still common due to variable clinical presentations of MSA. However, the clinical picture of MSA in its full-blown form is distinctive. The patient is hypomimic with orofacial and anterior neck dystonia resulting in a grinning smile akin to “risus sardonicus” and sometimes disproportionate antecollis. The voice is often markedly impaired with a characteristic quivering high-pitched dysarthria. The motor disorder of MSA is often mixed with parkinsonism, cerebellar ataxia, limb dystonia, myoclonus, and pyramidal features occurring at the same time. However, akinesia and rigidity are the predominating features in 80% of patients, and cerebellar ataxia within the remaining 20%. According to the predominant motor presentation, MSA patients may be labeled as parkinsonian or cerebellar variant (MSA-P, MSA-C). The diagnosis of MSA is largely based on clinical expertise, and this is well illustrated by the consensus diagnostic criteria, which comprise clinical features only (divided into four domains including autonomic dysfunction, parkinsonism, cerebellar dysfunction, and corticospinal tract dysfunction). Nevertheless, several autonomic function, imaging, neurophysiological, and biochemical studies have been proposed in the last decade to help in the differential diagnosis of MSA. No drug treatment consistently benefits patients with this disease. Indeed, parkinsonism often shows a poor or unsustained response to chronic levodopa therapy, however, one-third of the patients may show a moderate-to-good dopaminergic response initially. There is no effective drug treatment for cerebellar ataxia. On the other hand, features of autonomic failure such as orthostatic hypotension, urinary retention or incontinence, constipation, and impotence, may often be relieved if recognized by the treating physician. Novel symptomatic and neuroprotective therapies are urgently required.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bower J, Maraganore D, McDonnell S, Rocca W. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284–1288.
Tison F, Yekhlef F, Chrysostome V, Sourgen C. Prevalence of multiple system atrophy. Lancet 2000; 355(9202):495–496.
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999;354:1771–1775.
Wermuth L, Joensen P, Bunger N, Jeune B. High prevalence of Parkinson’s disease in the Faroe Islands. Neurology 1997;49(2):426–432.
Chio A, Magnani C, Schiffer D. Prevalence of Parkinson’s disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998;13(3):400–405.
Trenkwalder C, Schwarz J, Gebhard J, Ruland D, Trenkwalder P, Hense HW, et al. Starnberg trial on epidemiology of Parkinsonism and hypertension in the elderly. Prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 1995;52(10): 1017–1022.
Nee LE, Gomez MR, Dambrosia J, Bale S, Eldridge R, Polinsky RJ. Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res 1991;1: 9–13.
Gilman S, Low P, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 1998;8:359–362.
Hanna P, Jankovic J, Kirkpatrick JB. Multiple system atrophy: the putative causative role of environmental toxins. Arch Neurol 1999;56:90–94.
Vanacore N, Bonifati V, Fabbrini G, Colosimo C, Marconi R, Nicholl D, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. Neurology 2000;54:114–119.
Quinn N. Multiple system atrophy—the nature of the beast. J Neurol Neurosurg Psychiatry 1989; 52(Suppl):78–89.
Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement Disorders 3. London: Butterworth-Heinemann, 1994:262–281.
Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117(Pt 4):835–845.
Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson’s disease—a retrospective comparison. Acta Neurol Scand 1995; 91(2):98–102.
Quinn NP, Wenning G, Marsden CD. The Shy Drager syndrome. What did Shy and Drager really describe? Arch Neurol 1995;52(7):656–657.
Litvan I, Booth V, Wenning GK, Bartko JJ, Goetz CG, McKee A, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm 1998; 105(2–3):217–227.
Colosimo C, Vanacore N, Bonifati V, Fabbrini G, Rum A, De Michele G, et al. Clinical diagnosis of multiple system atrophy: level of agreement between Quinn’s criteria and the consensus conference guidelines. Acta Neurol Scand 2001;103:261–264.
Osaki Y, Wenning GK, Daniel SE, Hughes A, Lees AJ, Mathias CJ, et al. Do published criteria improve clinical diagnostic accuracy in multiple system atrophy? Neurology 2002;59(10):1486–1491.
Ben Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997;48(2):384–393.
Wenning G, Tison F, Ben-Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord 1997;12(2):133–147.
Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch C. 123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992;42:556–561.
Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord 1993;8(4):453–458.
Wenning GK, Ben Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn NP. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000; 68(4):434–440.
Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry 2002;72(3):300–303.
Hughes A, Colosimo C, Kleedorfer B, Daniel SE, Lees AJ. The dopaminergic response in multiple system atrophy. J Neurol Neurosurg Psychiatry 1992;55:1009–1013.
Parati E, Fetoni V, Geminiani C, Soliveri P, Giovannini P, Testa D, et al. Response to L-Dopa in multiple system atrophy. Clin Neuropharmacol 1993;16(2):139–144.
Schulz J, Klockgether T, Petersen D, Jauch M, Müller-Schauenburg W, Spieker S, et al. Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994;57:1047–1056.
Wenning GK, Kraft E, Beck R, Fowler CJ, Mathias CJ, Quinn NP, et al. Cerebellar presentation of multiple system atrophy. Mov Disord 1997;12(1):115–117.
Watanabe H, Saito Y, Terao S, Ando T, Kachi T, Mukai E. Progression and prognosis in multiple system atrophy: an analysis of 230 Japanese patients. Brain 2002;125:1070–1083.
Gouider-Khouja N, Vidailhet M, Bonnet AM, Pichon J, Agid Y. “Pure” striatonigral degeneration and Parkinson’s disease: a comparative clinical study. Mov Disord 1995;10(3):288–294.
Holmberg B, Rosengren L, Karlsson JE, Johnels B. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson’s disease. Mov Disord 1998;13(1):70–77.
Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 2001;8(1):23–31.
Polinsky RJ, Brown RT, Lee GK, Timmers K, Culman J, Foldes O, et al. Beta-endorphin, ACTH, and catecholamine responses in chronic autonomic failure. Ann Neurol 1987;21(6):573–577.
Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson’s disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997;349(9069):1877–1881.
Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42(3 Pt 1):590–593.
Zoukos Y, Thomaides T, Pavitt DV, Cuzner ML, Mathias CJ. Beta-adrenoceptor expression on circulating mononuclear cells of idiopathic Parkinson’s disease and autonomic failure patients before and after reduction of central sympathetic outflow by clonidine. Neurology 1993;43(6):1181–1187.
Clarke CE, Ray PS, Speller JM. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson’s disease. Lancet 1999; 353(9161): 1329–1330.
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Neurol Sci 1996;144(1-2):218–219.
Bannister R, Mathias C. Investigation of autonomic disorders. In: Mathias C, Bannister R, eds. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford University Press, 1999:169–195.
Braune S, Auer A, Schulte-Mönting J, Schwerbrock S, Lücking C. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal subjects. Clin Auton Res 1996; 6:3–15.
Braune S, Schulte-Mönting J, Schwerbrock S, Lücking CH. Retest variation of cardiovascular parameters in autonomic testing. J Auton Nerv Syst 1996;60(3):103–107.
Riley D, Chemlinsky T. Autonomic nervous system testing may not distinguish multiple system atrophy from Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74(1):56–60.
Ziegler M, Lake C, Kopin I. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med 1977;296:293–297.
Polinsky R, Kopin I, Ebert M, Weise V. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981;31:1–7.
Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH. Cardiac uptake of (123I)MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53(5):1020–1025.
Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67(2):189–194.
Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000; 284(1):44–45.
Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000;27(5):566–573.
Kirby R, Fowler CJ, Gosling J, Bannister R. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986;49:554–562.
Beck R, Betts C, Fowler C. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J Urol 1994;151(5):1336–1341.
Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord 1996;11(2):157–162.
Schrag A, Good CD, Miszkiel K, Morris HR, Mathias CJ, Lees AJ, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000;54(3):697–702.
Klockgether T, Schroth G, Diener HC, Dichgans J. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990;53:297–305.
Wüllner U, Klockgether T, Petersen D, Naegele T, Dichgans J. Magnetic resonance imaging in hereditary and idiopathic ataxia. Neurology 1993;43:318–325.
Wakai M, Kume A, Takahashi A, Ando T, Hashizume Y. A study of parkinsonism in multiple system atrophy: clinical and MRI correlation. Acta Neurol Scand 1994;90(4):225–231.
Albanese A, Colosimo C, Bentivoglio A, Fenici R, Melillo G, Colosimo C, et al. Multiple system atrophy presenting as parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry 1995; 59: 144–151.
Konagaya M, Konagaya Y, Sakai M, Matsuoka Y, Hashizume Y. Progressive cerebral atrophy in multiple system atrophy. J Neurol Sci 2002;195(2):123–127.
Savoiardo M, Strada L Girotti F. Olivopontocerebellar atrophy: MR diagnosis and relationship to multisystem atrophy. Radiology 1990;174:693–696.
Drayer B, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S. Parkinson Plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986;159:493–498.
Pastakia B, Polinsky R, Di Chiro G, Simmon JT, Brown R, Wener L. Multiple system atrophy (Shy-Drager syndrome): MR imaging. Radiology 1986;159:499–502.
Olanow C. Magnetic resonance imaging in parkinsonism. Neurol Clin 1992;10:405–420.
Lang A, Curran T, Provias J, Bergeron C. Striatonigral degeneration: iron deposition in putamen correlated with the slit-like void signal of magnetic resonance imaging. Can J Neurol Sci 1994;21:311–318.
O’Brien C, Sung JH, McGeachie RE, Lee MC. Striatonigral degeneration: Clinical, MRI, and pathologic correlation. Neurology 1990;40:710–711.
Schwarz J, Weis S, Kraft E. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996;60: 98–101.
Stern M, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI. Magnetic resonance imaging in Parkinson’s disease and parkinsonian syndromes. Neurology 1989;39:1524–1526.
Schrag A, Kingsley D, Phatouros C, Mathias CJ, Lees AJ, Daniel SE, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy. J Neurol Neurosurg Psychiatry 1998;65(1):65–71.
Brooks D, Luthert P, Gadian D, Marsden C. Does signal-attentuation on high-field T2-weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationship between regional cerebral water proton T2-values and iron levels. J Neurol Neurosurg Psychiatry 1989;52:108–111.
Kraft E, Trenkwalder C, Auer DP. T2*-weighted MRI differentiates multiple system atrophy from Parkinson’s disease. Neurology 2002;59(8):1265–1267.
Konagaya M, Konagaya Y, Iida M. Clinical and magnetic resonance imaging study of extrapyramidal symptoms in multiple system atrophy. J Neurol Neurosurg Psychiatry 1994;57:1528–1531.
Konagaya M, Konagaya Y, Honda H, Iida M. A clinico-MRI study of extrapyramidal symptoms in multiple system atrophy—linear hyperintensity in the outer margin of the putamen. No To Shinkei 1993;45(6): 509–513.
Yekhlef F, Ballan G, Macia F, Delmer O, Sourgen C, Tison F. Routine MRI for the differential diagnosis of Parkinson’s disease, MSA, PSP, and CBD. J Neural Transm 2003;110(2):151–169.
Kraft E, Schwarz J, Trenkwalder C, Vogl T, Pfluger T, Oertel WH. The combination of hypointense and hyperintense signal changes on T2-weighted magnetic resonance imaging sequences: a specific marker of multiple system atrophy? Arch Neurol 1999;56(2):225–228.
Konagaya M, Sakai M, Matsuoka Y, Goto Y, Yoshida M, Hashizume Y. Patho-MR imaging study in the putaminal margin in multiple system atrophy. No To Shinkei 1998;50(4):383–385.
Schocke M, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W. Diffusion-weighted MRI differentiates the Parinson variant of multiple system atrophy from PD. Neurology 2002;58:575–580.
Seppi K, Schocke MF, Esterhammer R, Kremser C, Brenneis C, Mueller J, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 2003;60(6):922–927.
Schulz J, Skalej M, Wedekind D, Luft AR, Abele M, Voigt K, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson’s syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65–74.
Brenneis C, Seppi K, Schocke M, Müller J, Luginger E, Bösch S, et al. Voxel-based morphometry detects cortical atrophy in the parkinson variant of multiple system atrophy. Mov Disord 2003;18(10): 1132–1138.
Robbins TW, James M, Lange KW, Owen AM, Quinn NP, Marsden CD. Cognitive performance in multiple system atrophy. Brain 1992;115(Pt 1):271–291.
Davie CA, Wenning GK, Barker GJ, Tofts PS, Kendall BE, Quinn N, et al. Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy. Ann Neurol 1995; 37(2):204–210.
Federico F, Simone IL, Lucivero V, Mezzapesa DM, de Mari M, Lamberti P, et al. Usefulness of proton magnetic resonance spectroscopy in differentiating parkinsonian syndromes. Ital J Neurol Sci 1999;20(4): 223–229.
Ellis C, Lemmens G, Williams S, Simmons A, Leigh PN, Chaudhuri K. Striatal changes in striatonigral degeneration and Parkinson’s disease: a proton magnetic resonance spectroscopy study. Mov Disord 1996; 11:104.
Hu M, Simmons A, Glover A. Proton magnetic resonance spectroscopy of the putamen in Parkinson’s disease and multiple system atrophy. Mov Disord 1998;13:182.
Brooks D, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990;28:547–555.
Brooks D, Salmon E, Mathias C, Quinn N, Leenders K, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson’s disease, studied with PET. Brain 1990;113: 1539–1552.
Burn D, Sawle G, Brooks D. Differential diagnosis of Parkinson’s disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry 1994;57(3):278–284.
Brooks D, Ibanez V, Sawle G, Playford E, Quinn N, Mathias C, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992;31(2):184–192.
Burn D, Rinne J, Quinn N, Lees A, Marsden C, Brooks D. Striatal opioid receptor binding in Parkinson’s disease, striatonigral degeneration and Steele-Richardson-Olsewski syndrome A (11C)diprenorphine PET study. Brain 1995;118:951–958.
De Volder A, Francart J, Laterre C, Dooms G, Bol A, Michel C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989;26:239–247.
Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 1993;33:518–527.
Perani D, Bressi S, Testa D, Grassi F, Cortelli P, Gentrini S, et al. Clinical/metabolic correlations in multiple system atrophy. A fludeoxyglucose F18 positron emission tomography study. Arch Neurol 1995;52: 179–185.
Antonini A, Kazamuta k, Feigin A, Mandel F, Dhawan V, Margouleff C, et al. Differential diagnosis of parkinsonism with 18F-fluorodeoxyglucose and PET. Mov Disord 1998;13(2):268–274.
Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002;73(5):517–523.
Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994;36:166–175.
Rinne J, Burn DJ, Mathias CJ, Quinn NP, Marsden CD, Brooks DJ. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 1995;37:568–573.
Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, St. Laurent RT. Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. Ann Neurol 1995;38:176–185.
Shinotoh H, Inoue O, Hirayama K. Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993;56:467–472.
Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, et al. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993;43(6):17–20.
Brücke T, Wenger S, Asenbaum S. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol 1993;60:494–500.
Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17:45–53.
Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60–67.
Martinelli P, Coccagna G. Etude electromyographique du sphincter strie de l’anus dans trois cas de syndrome de Shy-Drager. In: Arbus L, Cadilhac J, eds. Electromyographie. Toulouse: Premieres Journees Languedociennes d’Electromyographie, 1978:321–326.
Eardley I, Quinn NP, Fowler CJ, Kirby RS, Parkhouse HF, Marsden CD, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989;64:360–362.
Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995;58(5): 618–621.
Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997;20(11):1396–1403.
Tison F, Arne P, Sourgen C, Chrysostome V, Yeklef F. The value of external anal sphincter electromyography for the diagnosis of multiple system atrophy. Mov Disord 2000;15(6):1148–1157.
Valldeoriola F, Valls-Sole J, Tolosa ES, Marti MJ. Striated anal sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995;10(5):550–555.
Giladi N, Simon ES, Korczyn AD, Groozman GB, Orlov Y, Shabtai H, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson’s disease. Muscle Nerve 2000;23: 731–734.
Libelius R, Johannson F. Quantitative electromyography of the external anal sphincter in Parkinson’s disease and multiple system atrophy. Muscle Nerve 2000;23:1250–1256.
Colosimo C, Inghilleri M, Chaudhuri KR. Parkinson’s disease misdiagnosed as multiple system atrophy by sphincter electromyography. J Neurol 2000;247:559–561.
Vodusek B. Sphincter EMG and differential diagnosis of multiple system atrophy. Mov Disord 2001; 16(4):600–607.
Wenning G, Smith SJM. Magnetic brain stimulation in multiple system atrophy. Mov Disord 1997; 12(3):452–453.
Abbruzzese G, Marchese R, Trompetto C. Sensory and motor evoked potentials in multiple system atrophy: comparative study with Parkinson’s disease. Mov Disord 1997;12(3):315–321.
Abele M, Schulz JB, Burk K, Topka H, Dichgans J, Klockgether T. Evoked potentials in multiple system atrophy (MSA). Acta Neurol Scand 2000;101(2):111–115.
Delalande I, Hache JC, Forzy G, Bughin M, Benhadjali J, Destee A. Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson’s disease and multiple system atrophy? Mov Disord 1998;13(3):446–452.
Montagna P, Martinelli P, Rizzuto N, Salviati A, Rasi F, Lugaresi E. Amyotrophy in Shy-Drager syndrome. Acta Neurol Belg 1983;83:142–157.
Cohen J, Low P, Fealey R, Sheps S, Jiang NS. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 1987;22:692–699.
Abele M, Schulz J, Burk K, Topka H, Dichgans J, Klockgether T. Nerve conduction studies in multiple system atrophy. Eur Neurol 2000;43(4):221–223.
Kofler M, Muller J, Wenning GK, Reggiani L, Hollosi P, Bosch S, et al. The auditory startle reaction in parkinsonian disorders. Mov Disord 2001;16(1):62–71.
Kofler M, Muller J, Seppi K, Wenning GK. Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. Clin Neurophysiol 2003;114(3):541–547.
Kume A, Takahashi A, Hashizume Y. Neuronal cell loss of the striatonigral system in multiple system atrophy. J Neurol Sci 1993;117:33–40.
Sung J, Mastri A, Segal E. Pathology of Shy-Drager syndrome. J Neuropathol Exp Neurol 1979;38: 353–368.
Benarroch EE, Smithson IL, Low PA, Parisi JE. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol 1998;43(2): 156–163.
Shy G, Drager GA. A neurological syndrome associated with orthostatic hypotension. A clinicopathological study. Arch Neurol 1960;2:511–527.
Nakamura S, Ohnishi K, Nishimura M, Suenaga T, Akiguchi I, Kimura J, et al. Large neurons in the tuberomammillary nucleus in patients with Parkinson’s disease and multiple system atrophy. Neurology 1996; 46(6):1693–1696.
Papp M, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994;117:235–243.
Konno H, Yamamoto T, Iwasaki Y, Iizuka H. Shy-Drager syndrome and amyotrophic lateral sclerosis. Cytoarchitectonic and morphometric studies of sacral autonomic neurons. J Neurol Sci 1986;73(2): 193–204.
Daniel S. The neuropathology and neurochemistry of multiple system atrophy. In: Mathias C, Bannister R, eds. Autonomic Failure: A Textbook of Clinical Disorders of the Autonomic Nervous System. Oxford: Oxford University Press, 1999:321–328.
Oppenheimer DR. Lateral horn cells in progressive autonomic failure. J Neurol Sci 1980;46(3): 393–404.
Bannister R, Oppenheimer D. Degenerative diseases of the nervous system associated with autonomic failure. Brain 1972;95:457–474.
Tsuchiya K, Ozawa E, Haga C, Watabiki S, Ikeda M, Sano M, et al. Constant involvement of the Betz cells and pyramidal tract in multiple system atrophy: a clinicopathological study of seven autopsy cases. Acta Neuropathol (Berl) 2000;99:628–636.
Wakabayashi K, Ikeuchi T, Ishikawa A, Takahashi H. Multiple system atrophy with severe involvement of the motor cortical areas and cerebral white matter. J Neurol Sci 1998; 156(1): 114–117.
Konagaya M, Sakai M, Matsuoka Y, Konagaya Y, Hashizume Y. Multiple system atrophy with remarkable frontal lobe atrophy. Acta Neuropathol (Berl) 1999;97(4):423–428.
Sima A, Caplan M, D’Amato CJ, Pevzner M, Furlong JW. Fulminant multiple system atrophy in a young adult presenting as motor neuron disease. Neurology 1993;43:2031–2035.
Hayashi M, Isozaki E, Oda M, Tanabe H, Kimura J. Loss of large myelinated nerve fibres of the recurrent laryngeal nerve in patients with multiple system atrophy and vocal cord palsy. J Neurol Neurosurg Psychiatry 1997; 62:234–238.
Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989;15(1):13–26.
Yamada T, McGeer PL. Oligodendroglial microtubular masses: an abnormality observed in some human neurodegenerative diseases. Neurosci Lett 1990;120:163–166.
Arima K, Nakamura M, Sunohara N, Ogawa M, Anno M, Izumiyama Y, et al. Ultrastructural characterization of the tau-immunoreactive tubules in the oligodendroglial perikarya and their inner loop processes in progressive supranuclear palsy. Acta Neuropathol (Berl) 1997;93(6):558–566.
Chin SS, Goldman JE. Glial inclusions in CNS degenerative diseases. J Neuropathol Exp Neurol 1996; 55(5):499–508.
Wenning G, Quinn N. Are Lewy bodies non-specific epiphenomena of nigral damage? Mov Disord 1994; 9(3):378–379.
Papp M, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94: 79–100.
Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998;57(12):1099–1111.
Gai WP, Pountney DL, Power JH, Li QX, Culvenor JG, McLean CA, et al. alpha-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp Neurol 2003;181(1): 68–78.
Papp M, Lantos PI. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992;107:172–182.
Cairns NJ, Atkinson PF, Hanger DP, Anderton BH, Daniel SE, Lantos PL. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. Neurosci Lett 1997;230(1):49–52.
Dickson DW, Lin W, Liu WK, Yen SH. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 1999;9(4):721–732.
Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 1998;3(6):462–465.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388(6645):839–840.
Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998;249(2-3):180–182.
Wakabayashi K, Hayashi S, Kakita A, Yamada M, Toyoshima Y, Yoshimoto M, et al. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol (Berl) 1998;96:445–452.
Arima K, Ueda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol (Berl) 1998;96:439–444.
Tu P, Galvin JE, Baba M, Giasson B, Tomita T, Leight S, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998; 44(3): 415–422.
Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, Goedert M. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson’s disease and dementia with Lewy bodies. Neurosci Lett 1998;251(3):205–208.
Trojanowski JQ. Tauists, Baptists, Syners, Apostates, and new data. Ann Neurol 2002;52(3): 263–265.
Gai WP, Power JH, Blumbergs PC, Blessing WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet 1998;352(9127):547–548.
Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann Neurol 1998;44(3 Suppl 1): S115–S120.
Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 2001;184(1):71–75.
Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, et al. The role of glial cells in Parkinson’s disease. Curr Opin Neurol 2001;14(4):483–489.
Allan SM, Rothwell NJ. Cytokines and acute neurodegeneration. Nat Rev Neurosci 2001;2(10): 734–744.
Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson’s disease. Neurosci Lett 1994;172(1-2):151–154.
Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, et al. FcepsilonRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999;19(9):3440–3447.
Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994; 165(1-2):208–210.
McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 2001;169(2):219–230.
Aloe L, Fiore M. TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunore-activity and alters grooming behavior. Neurosci Lett 1997;238(1-2):65–68.
Gerhard A, Banati RB, Goerres GB, Cagnin A, Myers R, Gunn RN, et al. [(11)C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology 2003;61(5):686–689.
Wenning G, Granata R, Laboyrie PM, Quinn NP, Jenner P, Marsden CD. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 1996;11(5):522–532.
Wenning G, Granata R, Puschban Z, Scherfler C, Poewe W. Neural transplantation in animal models of multiple system atrophy: a review. J Neural Transm 1999;55:103–113.
Scherfler C, Puschban Z, Ghorayeb I, Goebel GP, Tison F, Jellinger K, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neuroscience 2000; 99(1):43–54.
Ghorayeb I, Puschban Z, Fernagut PO, Scherfler C, Rouland R, Wenning GK, et al. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 2001;167(1):133–147.
Waldner R, Puschban Z, Scherfler C, Seppi K, Jellinger K, Poewe W, et al. No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). Neuroscience 2001;102(3):581–592.
Ghorayeb I, Fernagut PO, Hervier L, Labattu B, Bioulac B, Tison F. A “single toxin-double lesion” rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 2002;115(2):533–546.
Stefanova N, Puschban Z, Fernagut PO, Brouillet E, Tison F, Reindl M, et al. Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system atrophy). Acta Neuropathol (Berl) 2003;106(2):157–166.
Fernagut PO, Diguet E, Bioulac B, Tison F. MPTP potentiates 3-nitropronionic acid-induced striatal damage in mice: reference to striatonigral degeneration. Exp Neurol. 2004;185(1):47–62.
Ghorayeb I, Fernagut PO, Aubert I, Bezard E, Poewe W, Wenning GK, et al. Toward a primate model of L-dopaunresponsive parkinsonism mimicking striatonigral degeneration. Mov Disord 2000;15(3):531–536.
Ghorayeb I, Fernagut PO, Stefanova N, Wenning GK, Bioulac B, Tison F. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335(1):34–38.
Kahle PJ, Neumann M, Ozmen L, Muller V, Jacobsen H, Spooren W, et al. Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes. EMBO Rep 2002;3(6):583–588.
Zuscik M, Sands S, Ross SA, Waugh DJJ, Gaivin RJ, Morilak D, et al. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Nat Med 2000;6(12):1388–1394.
Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, et al. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or cografts. Neuroscience 2000;95(2):377–388.
Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95(1):38–48.
Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277(13):1046–1051.
Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN et al. A double-blind, doseresponse study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51(1):120–124.
Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, doseranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res 2001;11(4): 235–242.
Alam M, Smith G, Bleasdale-Barr K, Pavitt DV, Mathias CJ. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J Hypertens 1995; 13(12 Pt 2):1664–1669.
Raimbach SJ, Cortelli P, Kooner JS, Bannister R, Bloom SR, Mathias CJ. Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes. Clin Sci (Lond) 1989;77(6):623–628.
Mathias CJ, Fosbraey P, da Costa DF, Thornley A, Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br Med J (Clin Res Ed) 1986;293(6543):353–354.
Perera R, Isola L, Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin Auton Res 1995;5(4):211–213.
Winkler A, Marsden J, Parton M, Watkins P, Chaudhuri K. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 2001;16:233–239.
Mathias C, Kimber JR. Postural hypotension: causes, clinical features, investigation, and management. Annu Rev Med 1999;50:317–326.
Sakakibara R, Hattori T, Uchiyama T, Suenaga T, Takahashi H, Yamanishi T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000;79:191–195.
Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol 2002; 9(3):195–199.
Zesiewicz T, Helal M, Hauser RA. Sildenafil Citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson’s disease. Mov Disord 2000;15(2):305–308.
Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71(3):371–374.
Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord 2001;16(6):1176–1177.
Iranzo A, Santamaria J, Tolosa E, Barcelona Multiple System Atrophy Study Group. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Lancet 2000;356:1329–1330.
Lees A. The treatment of the motor disorder of multiple system atrophy. In: Mathias C, Bannister R, eds. Autonomic Failure. Oxford: Oxford University Press, 1999:357–363.
Lees A, Bannister R. The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J Neurol Neurosurg Psychiatry 1981;44:347–351.
Colosimo C, Merello M, Pontieri FE. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J Neurol 1996;243(5):422–425.
Lang AE, Lozano A, Duff J, Tasker R, Miyasaki J, Galvez-Jimenez N, et al. Medial pallidotomy in late-stage Parkinson’s disease and striatonigral degeneration. Adv Neurol 1997;74:199–211.
Visser-Vandewalle V, Temel Y, Colle H, van der LC. Bilateral high-frequency stimulation of the subthalamic nucleus in patients with multiple system atrophy—parkinsonism. Report of four cases. J Neurosurg 2003; 98(4):882–887.
Graham J, Oppenheimer DR. Orthostatic-hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28–34.
Johnsen J, Miller VT. Tobacco intolerance in multiple system atrophy. Neurology 1986;36: 986–988.
Wenning GK, Seppi K, Sampaio C, Quinn NP, Poewe W, Tison F. European Multiple System Atrophy Study Group (EMSA-SG): Validation of the Unified MSA Rating Scale (UMSARS). Mov Disord 2002;17(Suppl 5):252.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Geser, F., Wenning, G.K. (2005). Multiple System Atrophy. In: Litvan, I. (eds) Atypical Parkinsonian Disorders. Current Clinical Neurology. Humana Press. https://doi.org/10.1385/1-59259-834-X:335
Download citation
DOI: https://doi.org/10.1385/1-59259-834-X:335
Publisher Name: Humana Press
Print ISBN: 978-1-58829-331-2
Online ISBN: 978-1-59259-834-2
eBook Packages: MedicineMedicine (R0)